ZZZhengping Zhuang

Zhengping Zhuang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhengping Zhuang has a total of 321 co-authors. Here are the top co-authors by number of shared publications:

  • Chunzhang Yang

    Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA

    25 shared publications
  • Jie Lu

    Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, NIH, Bethesda, Maryland

    12 shared publications
  • Russell R. Lonser

    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland

    11 shared publications
  • Barbara Ikejiri

    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland

    7 shared publications
  • Chao Zhang

    Department of Orthopedics, Xinqiao Hospital, the Third Military Medical University, Chongqing, China

    7 shared publications
  • Christopher S. Hong

    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA

    7 shared publications

Latest Publications

  • Retraction
    Open Access

    Retraction: Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair

    by Peng Lv, Yue Wang, Jie Ma, Zheng Wang, Jing-Li Li, Christopher S. Hong, Zhengping Zhuang, Yi-Xin Zeng

    Https://doi.org/10.18632/oncotarget.28727 Peng Lv, Yue Wang, Jie Ma, Zheng Wang, Jing-Li Li, Christopher S. Hong, Zhengping Zhuang, Yi-Xin Zeng

  • Open Access

    Switching from Fatty Acid Oxidation to Glycolysis Improves the Outcome of Acute‐On‐Chronic Liver Failure

    by Zujiang Yu, Jingjing Li, Zhigang Ren, Ranran Sun, Yang Zhou, Qi Zhang, Qiongye Wang, Guangying Cui, Juan Li, Ang Li, et al.

    Acute‐on‐chronic liver failure (ACLF) has a high mortality rate. Metabolic reprogramming is an important mechanism for cell survival. Herein, the metabolic patterns of ACLF patients are analyzed. An in vitro model of ACLF is established using Chang liver cells under hyperammonemia and hypoxia. A randomized clinical trial (ChiCTR‐OPC‐15006839) is performed with patients receiving L‐ornithine and L‐aspartate (LOLA) daily intravenously (LOLA group) and trimetazidine (TMZ) tid orally (TMZ group) based on conventional treatment (control group). The primary end point is 90‐day overall survival, and overall survival is the secondary end point. By analyzing metabolic profiles in liver tissue samples from hepatitis B virus (HBV)‐related ACLF patients and the controls, the metabolic characteristics of HBV‐related ACLF patients are identified: inhibited glycolysis, tricarboxylic acid cycle and urea cycle, and enhanced fatty acid oxidation (FAO) and glutamine anaplerosis. These effects are mainly attributed to hyperammonemia and hypoxia. Further in vitro study reveals that switching from FAO to glycolysis could improve hepatocyte survival in the hyperammonemic and hypoxic microenvironment. Importantly, this randomized clinical trial confirms that inhibiting FAO using TMZ improves the prognosis of patients with HBV‐related ACLF. In conclusion, this study provides a practical strategy for targeting metabolic reprogramming using TMZ to improve the survival of patients with HBV‐related ACLF.


  • RDNA-18. TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5/p25: A NOVEL THERAPEUTIC APPROACH AGAINST GLIOBLASTOMA

    by Emeline Tabouret, Herui Wang, Niranjana Amin, Christophe Redon, Jinkyu Jung, Jing Cui, Qi Song, Limin Liu, Romain Appay, Anjali Vyas, et al.

    Increasing evidence suggests a role of increased expression of CDK5 in cancer progression. Here, we examined the efficacy of selective inhibition of CDK5 in glioblastoma, the most frequent and aggressive primary brain tumor in adults. TP5 is a small peptide developed by National Institutes of Health which selectively inhibits aberrant and hyperactive CDK5/p25 while preserving the physiological CDK5/p35 functions. This peptide was modified to facilitate passage through blood brain barrier. METHODS & We demonstrated that TP5 decreased the activity but not the expression of CDK5 and p35. TP5 alone, but not the scrambled peptide, impacted cell viability and colony formation of glioblastoma cell lines and increased early and late apoptosis. Analyzing the pH2A.X expression by Immunofluorescence and Western Blot, we observed that TP5 increased the DNA damage in a dose dependent manner. TP5 impaired the DNA repair by reducing the G2 phase and decreased the phosphorylation of ATM. Whereas CDK5 activity is increased by DNA-damaging agents such as temozolomide (TMZ) and irradiation (IR), we observed that the addition of TP5 to either TMZ or IR was synergistic on colony formation due to an accumulation of DNA damages. Concomitant use of TP5 and either TMZ or IR increased the pH2A.X foci number and expression, inhibited the G2 arrest induced by these therapies and the phosphorylation of ATM. TP5 alone (300 mg/kg every 2 days) decreased the tumor volume of orthotopic glioblastoma mouse-model in a safety and dose-escalation experiment (4 mice per group: control, scrambled peptide, 100mg/kg, 300mg/kg). The treatment was well tolerated as the mouse weights were stable during the treatment and no hematologic, renal, pancreatic or liver function toxicities were observed (blood test). CONCLUSIONS: TP5 is a promising therapy for glioblastoma patients alone or in association with temozolomide and radiotherapy targeting a unique aspect of tumor biology.

  • IMMU-38. TARGETING HYPOXIA DOWNSTREAM SIGNALING PROTEIN, CAIX FOR CAR-T CELL THERAPY AGAINST GLIOBLASTOMA (GBM)

    by Jing Cui, Qi Zhang, Qi Song, Herui Wang, Xiaoyu Cao, Timothy Westlake, Kaiyong Yang, Jared Rosenblum, Yu Yao, Mark Gilbert, et al.

    The need for novel therapies for GBM treatment is well established. While chimeric antigen receptor (CAR)-engineered T cells represent a promising cancer treatment modality, highly expressed unique cell surface antigens are essential. We postulated that tumor-specific surface antigens related to hypoxia signaling may have potential. Carbonic Anhydrase IX (CAIX) is active in settings of unbalanced pH driving proton transport to the extracellular medium in response to decreased oxygen tension. We provide evidence that CAIX is highly expressed in GBM and thus a potentially suitable target which we investigated using CAIX-specific CAR-T cells against GBM cells. Patient GBM tissues were evaluated for CAIX protein expression. Antitumor CAIX-specific CAR T cells were developed and tested against four GBM cell lines: U251, LN 229, T98G, and A172. Cytotoxicity of CAIX CAR-T cells was assessed using the levels of IFN-γ, TNF-α, and IL-2 released when co-cultured with tumor cells. Direct intra-tumor injection of CAR-T cells into intracranial GBM xenograft mouse model was used for in vivo testing. We confirmed high expression of CAIX in of human GBM. The viral construct of CAIX-specific CAR-T cells generated was tested against GBM cell lines. In vitro, CAIX-specific CAR-T cells displayed enhanced GBM cells cytolysis and increased IFN-γ, TNF-α, and IL-2 production. The CAR-T cells showed a specific CAIX-dependent recognition of GBM cells. Direct intra-tumor injection of the CAR-T cells into an intracranial GBM xenograft mouse model efficiently suppressed the growth of GBM cells and significantly prolonged mouse survival. In approximately 20%, CAIX specific CAR-T cells completely eradicated GBM tumors. The present study demonstrates the specificity of CAIX under hypoxic conditions in GBM. The results also show that CAIX represents a viable target for CAR-T cells and may be a promising strategy to treat GBM.

  • Open Access

    Publisher Correction: PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

    by Chao Hu, Mengxia Yu, Yanling Ren, Kongfei Li, Dominic M. Maggio, Chen Mei, Li Ye, Juying Wei, Jie Jin, Zhengping Zhuang, et al.

    A correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.


  • Open Access

    Recurrent somatic mutations of PRKAR1A in isolated cardiac myxoma

    by Jian He, Mingju Sun, Enyou Li, Yingyong Hou, Matthew J. Shepard, Di Chen, Karel Pacak, Changsong Wang, Lei Guo, Zhengping Zhuang, et al.

    Recurrent somatic mutations of PRKAR1A in isolated cardiac myxoma Recurrent somatic mutations of PRKAR1A in isolated cardiac myxoma


  • Open Access

    PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

    by Chao Hu, Mengxia Yu, Yanling Ren, Kongfei Li, Dominic M. Maggio, Chen Mei, Li Ye, Juying Wei, Jie Jin, Zhengping Zhuang, et al.

    Patients with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndromes have a poor prognosis marked by an increased resistance to chemotherapy. An urgent need exists for adjuvant treatments that can enhance or replace current therapeutic options. Here we show the potential of LB100, a small-molecule protein phosphatase 2 A (PP2A) inhibitor, as a monotherapy and chemosensitizing agent for sAML using an in-vitro and in-vivo approach. We demonstrate that LB100 decreases cell viability through caspase activation and G2/M cell-cycle arrest. LB100 enhances daunorubicin (DNR) cytotoxicity resulting in decreased xenograft volumes and improved overall survival. LB100 profoundly upregulates miR-181b-1, which we show directly binds to the 3′ untranslated region of Bcl-2 mRNA leading to its translational inhibition. MiR-181b-1 ectopic overexpression further diminishes Bcl-2 expression leading to suppression of sAML cell growth, and enhancement of DNR cytotoxicity. Our research highlights the therapeutic potential of LB100, and provides new insights into the mechanism of LB100 chemosensitization.


  • Open Access

    Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha

    by Chao Zhang, Chunzhang Yang, Michael J. Feldman, Herui Wang, Ying Pang, Dominic M. Maggio, Dongwang Zhu, Cody L. Nesvick, Pauline Dmitriev, Petra Bullova, et al.

    Histone deacetylase inhibitors (HDACis) are a potent class of tumor-suppressive agents traditionally believed to exert their effects through loosening tightly-wound chromatin resulting in de-inhibition of various tumor suppressive genes. Recent literature however has shown altered intratumoral hypoxia signaling with HDACi administration not attributable to changes in chromatin structure. We sought to determine the precise mechanism of HDACi-mediated hypoxia signaling attenuation using vorinostat (SAHA), an FDA-approved class I/IIb/IV HDACi. Through an in-vitro and in-vivo approach utilizing cell lines for hepatocellular carcinoma (HCC), osteosarcoma (OS), and glioblastoma (GBM), we demonstrate that SAHA potently inhibits HIF-a nuclear translocation via direct acetylation of its associated chaperone, heat shock protein 90 (Hsp90). In the presence of SAHA we found elevated levels of acetyl-Hsp90, decreased interaction between acetyl-Hsp90 and HIF-a, decreased nuclear/cytoplasmic HIF-α expression, absent HIF-α association with its nuclear karyopharyin Importin, and markedly decreased HIF-a transcriptional activity. These changes were associated with downregulation of downstream hypoxia molecules such as endothelin 1, erythropoietin, glucose transporter 1, and vascular endothelial growth factor. Findings were replicated in an in-vivo Hep3B HRE-Luc expressing xenograft, and were associated with significant decreases in xenograft tumor size. Altogether, this study highlights a novel mechanism of action of an important class of chemotherapeutic.


  • ZEB1 expression is increased in IDH1-mutant lower-grade gliomas

    by Cody L. Nesvick, Chao Zhang, Nancy A. Edwards, Blake K. Montgomery, Michaela Lee, Chunzhang Yang, Herui Wang, Dongwang Zhu, John D. Heiss, Marsha J. Merrill, et al.

    Transcription factors that induce epithelial-mesenchymal transition (EMT) promote invasion, chemoresistance and a stem-cell phenotype in epithelial tumors, but their roles in central nervous system tumors are not well-understood. We hypothesized these transcription factors have a functional impact in grades II–III gliomas. Using the National Cancer Institute (NCI) Repository for Molecular Brain Neoplasia Data (REMBRANDT) and the Cancer Genome Atlas (TCGA) Lower-Grade Glioma (LGG) data, we determined the impact of EMT-promoting transcription factors (EMT-TFs) on overall survival in grades II–III gliomas, compared their expression across common genetic subtypes and subsequently validated these findings in a set of 31 tumors using quantitative real-time polymerase chain reaction (PCR) and immunohistochemistry. Increased expression of the gene coding for the transcriptional repressor Zinc Finger E box-binding Homeobox 1 (ZEB1) was associated with a significant increase in overall survival (OS) on Kaplan–Meier analysis. Genetic subtype analysis revealed that ZEB1 expression was relatively increased in IDH1/2-mutant gliomas, and IDH1/2-mutant gliomas expressed significantly lower levels of many ZEB1 transcriptional targets. Similarly, IDH1/2-mutant tumors expressed significantly higher levels of targets of microRNA 200C (MIR200C), a key regulator of ZEB1. In a validation study, ZEB1 mRNA was significantly increased in IDH1-mutant grades II–III gliomas, and ZEB1 protein expression was more pronounced in these tumors. Our findings demonstrate a novel relationship between IDH1/2 mutations and expression of ZEB1 and its transcriptional targets. Therapy targeting ZEB1-associated pathways may represent a novel therapeutic avenue for this class of tumors.


  • Open Access

    Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome

    by Shuyu Hao, Christopher S. Hong, Jie Feng, Chunzhang Yang, Prashant Chittiboina, Junting Zhang, Zhengping Zhuang

    Maffucci syndrome is a rare disease characterized by multiple enchondromas and soft-tissue hemangiomas. Additionally, neuroendocrine tumors including pituitary adenomas have been described in these patients. The underlying genetic etiology lies in somatic mosaicism of mutations in isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2). This report describes a patient with Maffucci syndrome who presented with intracranial tumors of the skull base and suprasellar region. The patient underwent resection of both intracranial tumors, revealing histopathological diagnoses of chondrosarcoma and pituitary adenoma. DNA sequencing of the tumors was performed to identify common IDH1/2 mutations. Clinical, radiological, and biochemical assessments were performed. Genotypic studies used standard Sanger sequencing in conjunction with a target-specific peptide nucleic acid to detect IDH1 mutations in tumor tissues. DNA sequencing demonstrated identical IDH1 mutations (c.394C > T) in both tumors. To the authors’ knowledge, this report provides the first genetic evidence for the inclusion of pituitary adenomas among tumors characterizing Maffucci syndrome. In patients who are newly diagnosed with Maffucci syndrome, it is appropriate to monitor for development of pituitary pathology and neuroendocrine dysfunction.